2010 annual report

an educational 501(c)3 nonprofi t organization Fiscal Year 2010 Meetings CONFERENCE SCIENTIFIC ORGANIZERS LOCATION DATES Telomere Biology and DNA Repair Roger R. Reddel, Michael B. Kastan, Titia de Lange Ashmore, Australia Oct 9 – 14, ‘09 Overcoming the Crisis of TB and AIDS Anne E. Goldfeld, Stefan H.E. Kaufmann Arusha, Tanzania Oct 20 – 25, ‘09 NF-kB in Inflammation and Disease Michelle A. Kelliher, Manolis Pasparakis, Jürg Tschopp Santa Fe, NM, USA Jan 5 – 10 Advances in Biopharmaceuticals John M. McPherson, Thomas F. Bumol Midway, UT, USA Jan 8 – 13 Structural Biology* Alasdair C. Steven, Pamela J. Bjorkman, Andrej Sali Breckenridge, CO, USA Jan 8 – 13 Structural Genomics: Expanding the Ian A. Wilson, Kurt Wüthrich, Soichi Wakatsuki, Breckenridge, CO, USA Jan 8 – 13 Horizons of Structural Biology* Christine A. Orengo Triglycerides and Triglyceride-Rich Robert H. Eckel, Ira J. Goldberg, Ruth McPherson Big Sky, MT, USA Jan 9 – 14 Particles in Health and Disease Alzheimer’s Disease Beyond Ab JoAnne McLaurin, Tony Wyss-Coray Copper Mountain, CO, USA Jan 10 – 15 Molecular Basis for Biological Membrane Tom A. Rapoport, Sandra L. Schmid Snowbird, UT, USA Jan 10 – 15 Organization and Dynamics HIV Biology and Pathogenesis Thomas J. Hope, Katherine A. Jones, Daniel C. Douek Santa Fe, NM, USA Jan 12 – 17 RNA Silencing: Mechanism, Biology and Application Phillip D. Zamore, Beverly L. Davidson Keystone, CO, USA Jan 14 – 19 Molecular Basis for Chromatin Jonathan Widom, Geeta Narlikar, Dinshaw J. Patel Taos, NM, USA Jan 17 – 22 Structure and Regulation Hypoxia: Molecular Mechanisms of Navdeep S. Chandel, Peter J. Ratcliffe, Volker H. Haase, Keystone, CO, USA Jan 19 – 24 Oxygen Sensing and Response Pathways Agnes Görlach Adipose Tissue Biology* Sheila Collins, Karsten Kristiansen, Silvia Corvera Keystone, CO, USA Jan 24 – 29 Neuronal Control of Appetite, Kevin L. Grove, Michael A. Cowley, Rexford S. Ahima Keystone, CO, USA Jan 24 – 29 Metabolism and Weight* New Insights into Healthspan and Diseases of Aging: Sean M. Oldham, David A. Sinclair, Jan Vijg, Heidi Scrable Tahoe City, CA, USA Jan 31– Feb 5 From Functional to Molecular Senescence Role of Inflammation in Oncogenesis* Nina Bhardwaj, Giorgio Trinchieri Keystone, CO, USA Feb 7 – 12 Molecular and Cellular Biology of George C. Prendergast, Dmitry I. Gabrilovich Keystone, CO, USA Feb 7 – 12 Immune Escape in Cancer* Advances in Molecular Mechanisms of Atherosclerosis* Russell A. DeBose-Boyd, Christopher K. Glass Banff, AB, Canada Feb 12 – 17 The Macrophage: Intersection of Peter J. Murray, Sabine Ehrt, Ajay Chawla Banff, AB, Canada Feb 12 – 17 Pathogenic and Protective Inflammation* Antibiotics and Resistance: Challenges and Solutions Gerry Wright, Deborah Hung, Stewart L. Fisher Santa Fe, NM, USA Feb 14 – 19 Stem Cell Differentiation and Dedifferentiation Shinya Yamanaka, Fiona M. Watt Keystone, CO, USA Feb 15 – 20 Cell Biology of Virus Entry, Replication Margaret Kielian, Peter Sarnow, Terence S. Dermody, Taos, NM, USA Feb 16 – 21 and Pathogenesis Paul D. Bieniasz RNA Silencing Mechanisms in Plants Marjori Ann Matzke, James C. Carrington Santa Fe, NM, USA Feb 21 – 26 Tolerance and Autoimmunity Betty Diamond, Diane J. Mathis Taos, NM, USA Feb 21 – 26 Cilia, Signaling and Human Disease Peter Jackson, Tim Stearns Monterey, CA, USA Feb 21 – 26 Lymphocyte Activation and Gene Expression Leslie J. Berg, Lawrence E. Samelson, Facundo D. Batista Breckenridge, CO, USA Feb 27 – Mar 4 Angiogenesis in Health and Disease* Michael Simons, William C. Sessa Keystone, CO, USA Feb 28 – Mar 5 Cardiovascular Development and Repair* Doris A. Taylor, Brian H. Annex Keystone, CO, USA Feb 28 – Mar 5 Biomolecular Interaction Networks: Function and Disease Anna Panchenko, Teresa Przytycka, Andrea Califano Québec City, QC, Canada Mar 7 – 12 Cell Death Pathways: Apoptosis, Autophagy and Necrosis* Guido Kroemer, Junying Yuan, Eileen P. White Vancouver, BC, Canada Mar 12 – 17 Metabolism and Cancer Progression* Eileen P. White, Craig B. Thompson, Chi Van Dang Vancouver, BC, Canada Mar 12 – 17 Receptors and Signaling in Plant Thomas Boller, Jen Sheen Tahoe City, CA, USA Mar 14 – 19 Development and Biotic Interactions HIV Vaccines* Wayne C. Koff, Lynn Morris, Marcus Altfeld Banff, AB, Canada Mar 21 – 26 Viral Immunity* Jonathan W. Yewdell, Akiko Iwasaki, Nicole L. La Gruta, Banff, AB, Canada Mar 21 – 26 Jack R. Bennink Nuclear Receptors: Signaling, W. Lee Kraus, Myles Brown, Karen Elizabeth Knudsen Keystone, CO, USA Mar 21 – 26 Gene Regulation and Cancer* Nuclear Receptors: Development, Carl S. Thummel, David D. Moore, Joyce J. Repa Keystone, CO, USA Mar 21 – 26 Physiology and Disease* New Paradigms in Cancer Therapeutics* Arul M. Chinnaiyan, William R. Sellers Victoria, BC, Canada Mar 23 – 28 Integration of Developmental Signaling Pathways* Jim Woodgett, Joseph Kelleher Victoria, BC, Canada Mar 23 – 28 G Protein-Coupled Receptors Brian K. Kobilka, Martin J. Lohse, Thue W. Schwartz Breckenridge, CO, USA Apr 7 – 12 Dynamics of Eukaryotic Transcription during Development Karen Adelman, Marc Timmers Big Sky, MT, USA Apr 7 – 12 Synapses: Formation, Function and Misfunction* Matthew B. Dalva, Peter Scheiffele, Yishi Jin Snowbird, UT, USA Apr 11 – 15 Toward Defining the Pathophysiology of Autistic Behavior* Pat Levitt, Joseph Piven Snowbird, UT, USA Apr 11 – 15 Malaria: New Approaches to Understanding Patrick E. Duffy, Jean Langhorne Copper Mountain, CO, USA Apr 11 – 16 Host-Parasite Interactions* Molecular Targets for Control of Vector-Borne Diseases: Kenneth D. Vernick, Elena A. Levashina, Gerry Killeen, Copper Mountain, CO, USA Apr 11 – 16 Bridging Lab and Field Research* Anthony A. James Islet Biology* Markus Stoffel, Doris A. Stoffers, Per-Olof Berggren Whistler, BC, Canada Apr 12 – 17 Diabetes* Juleen R. Zierath, Philippe Froguel, Nancy A. Thornberry, Whistler, BC, Canada Apr 12 – 17 Michael P. Czech Computer-Aided Drug Design* Michael K. Gilson, Catherine E. Peishoff, Jeff Blaney Whistler, BC, Canada Apr 20 – 25 New Directions in Small Molecule Drug Discovery* William J. Greenlee, George Hartman, Anna K. Mapp Whistler, BC, Canada Apr 20 – 25 Developmental Origins and Epigenesis in Human Judith Swain, Peter D. Gluckman, Michael Meaney, Singapore Apr 26 – 30 Health and Disease Anne Ferguson-Smith Bioactive Lipids: Biochemistry and Diseases Shuh Narumiya, Takao Shimizu, Garret A. FitzGerald Kyoto, Japan Jun 6 – 11 Innate Immunity: Mechanisms Linking with Luke A.J. O’Neill, Kate A. Fitzgerald, Averil I. Ma Dublin, Ireland Jun 7 – 12 Adaptive Immunity *Joint meetings from tHe cHaIr of tHe board

highlight of 2010 for me was undoubtedly being appointed Chair of the Board of Directors of Keystone Symposia. I have been involved with Keystone ASymposia in various capacities for the past two decades. During that time, I have become even more convinced of the invaluable role this nonprofi t plays in elevating scientifi c discourse, enhancing careers – particularly those of newer investigators – and accelerating life science discovery. Keystone Symposia offers a unique environment for life science researchers to come together to discuss the latest developments.

Has the new world of electronic communications made a physical meeting obsolete? The feedback suggests otherwise. For the 2010 season, 91% of attendees rated the meeting in which they participated to be “Excellent” or “Very Good,” while 97% of attendees said they would attend another Keystone Symposia conference. These ratings are as high if not higher than in previous years – and particularly impressive given that participants reported attending a smaller number of conferences overall during the year. Furthermore, many attendees reported that, as a result of the Keystone Symposia conference, they formed a collaboration or learned something, such as a new technique, that saved them time and money.

Thanks to the generous support of corporate, foundation, government and individual donors, we are able not only to offer an increasing number of scholarships and travel Juleen R. Zierath, Ph.D. awards to deserving investigators, but also to keep the cost of attendance as affordable as possible for everyone. I believe another overlooked outcome of this support is that the meetings can focus strictly on the science and retain a collegial, non-commercial atmosphere unclouded by political and other agendas. We are extremely grateful for the support given to Keystone Symposia from all corners of the scientifi c community. The combination of registration fee revenue and this external support has enabled Keystone Symposia to maintain a solid fi nancial position in challenging economic times.

I consider it truly an honor to be heading the governing board of Keystone Symposia. The organization is already fortunate to have very capable leadership in the form of CEO James Aiken, CSO Andrew Robertson and CFO Pamela Daugherty, plus others on the staff, Board of Directors and Scientifi c Advisory Board. As we approach Keystone Symposia’s 40th anniversary in 2012, my goal is to steer the organization in an even more international direction, in terms of both the locations where meetings are held and the composition of participants. Raising the profi le of the organization further on both a national and international scale will help to ensure continued, robust external support.

In the coming years, I look forward to meeting many of you, the participants, generous donors and others who make Keystone Symposia’s mission possible.

On behalf of the Board of Directors,

Juleen R. Zierath, Ph.D. Professor of Molecular Medicine and Surgery, Karolinska Institutet Chair of the Board, Keystone Symposia

1 from tHe cHIef eXecutIve offIcer

eystone Symposia aims to catalyze information exchange and instigate new ideas that accelerate life science discoveries to benefi t humanity, and we strive to do Kthis in an environment that augments the training and expands the wisdom of scientists worldwide to assure sustained scientifi c advances for the future. Maintaining the high quality of the symposia, so that our conferences are the most valuable of the ones scientists might choose to attend, is the goal of the Scientifi c Advisory Board, scientifi c organizers of each meeting and the staff involved in planning and implementation. I encourage you to read the more extensive comments overleaf of our Chief Scientifi c Offi cer, Andy Robertson, related to this topic.

The data in this Annual Report reveal both the impact of the economic downturn and our response to those circumstances. Attendance for 2010 was down about 12% from 2009’s record year. About half of that decline was planned – we reduced by six the number of meetings in 2010, mainly by postponing some of the smaller ones – and James W. Aiken, Ph.D. about half was unanticipated and likely due to the impact of the economic downturn on travel to conferences. Indeed, our end-of-year survey results on how many meetings our scientists attend per year showed a reversal of a four-year gradual upward trend back to the lower levels of 2006 and before. Faced with lower than anticipated registration revenue and a challenging fundraising environment, a rapid response by our staff both contained expenses while fi nding new donors and grant opportunities. This resulted in the year ending with Keystone Symposia avoiding any signifi cant net loss from operations (<0.1%), while increasing student, postdoctoral and minority scholarships to 711 (+6%) and increasing the portion of total expenses going to all educational programs (>83%) versus general administrative expenses (<13%) and fundraising costs (4%). It is positive to note that, as the charts on page 10 show, our average attendance declined only marginally from 2009.

Keystone Symposia is not presently supported by an endowment, although perhaps someday it will be. Each year, registration fees and generous gifts and grants from foundations, corporations, governments and individuals are needed to cover all operational costs. Funds for scholarships come from NIH and NSF grants, corporate and foundation gifts and the Keystone Symposia Future of Science Fund, which is supported mainly by annual personal donations. Currently, about one-third of all scholarship applicants are funded, so we are always striving to obtain funds for scholarships. In addition to the scholarship program, Keystone Symposia makes awards to scientists from developing countries to attend meetings in our Keystone Symposia Global Health Series. In 2010, 219 Travel Awardees attended these conferences. The Travel Award program is made possible by a grant from the Bill & Melinda Gates Foundation. This Report contains more information on pages 6-7 about this program.

We are at the beginning the 2010-2011 season, or fi scal 2011 for us in the offi ce. The potential fi nancial consequences of the world economic situation are still uncertain, and have reinforced the critical importance of making our conferences the most valuable of the ones from which our prospective attendees can choose. Keystone Symposia is committed to high quality and nurturing development of the next generation of scientists worldwide, but this requires more than we can do alone. Our success is highly dependent on the commitment of time by many scientists/mentors and by generous donations from supporting organizations and individuals.

I offer my sincere thanks to everyone who contributes to the success of Keystone Symposia.

James W. Aiken, Ph.D. President and Chief Executive Offi cer, Keystone Symposia

2 Milestones of the 2010 Fiscal Year

October 2009

Keystone Symposia held its first conference in Australia, on Telomere Biology and DNA Repair.

Following the Grand Challenges in Global Health conference, Keystone Symposia kicked off its fiscal year 2010 Global Health Series in Arusha, Tanzania with the meeting on Overcoming the Crisis of TB and AIDS.

March 2010

Keystone Symposia received a $1.37 million, five-year MARC (Minority Access to Research Careers) Ancillary Training Program grant from the National Institute of General Medical Sciences of the National Institutes of Health to fund its diversity initiatives.

April 2010

The eruption of the Eyjafjallajokull volcano in Iceland stranded at least 13 Global Health Travel Award winners and many other attendees of the joint meetings at Copper Mountain, Colorado, USA on Malaria and Vector-Borne Diseases. Also stranded were some of those attending the Diabetes and Islet Biology joint meetings in Whistler, British Columbia, Canada.

The volcanic ash cloud additionally caused cancellations by attendees and speakers at the joint meetings on Computer-Aided Drug Design and New Directions in Small Molecule Drug Discovery in Whistler, British Columbia because of their inability to travel to the site. However, web conferencing technology enabled most of the missing speakers to deliver their presentations remotely.

May 2010

Keystone Symposia held its first conference in Japan, a meeting in Kyoto on Bioactive Lipids: Biochemistry and Diseases. This was also the occasion of the award of the inaugural John Vane Scholarship.

Undeterred by travel risks due to the lingering volcanic ash cloud, a sell-out group of 456 attended Keystone Symposia’s meeting in Dublin, Ireland at Trinity College on Innate Immunity: Mechanisms Linking with Adaptive Immunity.

June 2010

Keystone Symposia graduated its second class of Fellows at the June 2010 Scientific Advisory Board meeting in Keystone. From left in the photo are Dana Crawford, Ph.D., Jameel Dennis, Ph.D., David Wilson, Ph.D., Fatima Rivas, Ph.D. and Dana-Lynn Koomoa, Ph.D.

Juleen R. Zierath, Ph.D., a diabetes researcher at Karolinska Institutet in Stockholm, was elected Chair of the Board of Keystone Symposia, replacing Curtis C. Harris, M.D. of NCI who became an emeritus board member upon conclusion of his three- year term. Additionally, Gary J. Nabel, M.D., Ph.D. and Terry J. Opgenorth, Ph.D. joined the Board. 3 settInG tHe staGe for serendIpIty by Andrew Robertson, Chief Scientifi c Offi cer, Keystone Symposia

recently took part in a professional development workshop, along with about 20 other participants, that explored how groups solve problems. One of the most revealing Iexercises focused on anagrams, puzzles in which letters in words or phrases are scrambled and the aim is to unscramble them. Example: OILY BOG (answer = “biology”).

The anagram exercise was one of several different exercises taking place simultaneously in different rooms; typically, a handful of workshop participants were working on the puzzle at any given time, and occasionally someone would leave and another person might wander in. When I fi rst wandered in, about half of the dozen or so words and phrases had been identifi ed. Participants already in the room were gazing at the puzzle, with a few articulating possible solutions out loud. When I looked at the scrambled letters, I thought I saw a solution and blurted it out. My solution was incorrect but one of the people already in the room immediately shouted, “I got it!” and fi lled in the solution, which vaguely resembled my idea.

Andrew D. Robertson, Ph.D. It is no great stretch for me to see the analogy between how workshop participants solved the anagrams and what happens at Keystone Symposia’s conferences. At the workshop, my contribution to solving the puzzles was based on progress already made by others; my crude input then helped someone else solve the puzzle. In other words, our progress depended on where we were at any given moment, as well as extensive give-and- take among the puzzle-solvers and a willingness to be wrong in front of others. In fact, trying out and sharing reasonable but incorrect answers was key to moving the group towards solutions. At Keystone Symposia, we help attendees develop a critical perspective of their fi eld and we provide a forum for extensive discussion; we aim for an environment where all attendees feel welcome to share ideas freely, regardless of how these ideas might pan out.

Some interesting and closely related principles regarding group dynamics and creativity were recently summarized by Venessa Miemis on her website, “Emergent by Design” (www.emergentbydesign.com). Here, I adapt a few principles that seem most relevant to what we aim for at Keystone Symposia.

Quality of Research The paramount principle at Keystone Symposia is to ensure the highest quality of research presented at our meetings. We are proud of our success at attracting speakers who are world-leading researchers, including Nobel Laureates and members of national academies. In addition to bringing established investigators to the program, Keystone Symposia invests considerable effort in identifying up-and-coming researchers and providing them with opportunities to share their research.

Optimal Flow of Information The second principle is to maximize the fl ow of information among meeting attendees. To accomplish this, research abstracts are shared online (assuming the author grants permission) with registered attendees well before the meeting is convened. At the meetings, talks and posters deliver the latest research results and serve as opportunities for collaborative development of new ideas. Finally, unstructured time, shared meals and the proximity among attendees engendered by our retreat-like venues provide extensive opportunities for the sharing of information.

The success and impact of information sharing at Keystone Symposia meetings in 2010 can be seen in stories offered by attendees in their post-conference surveys. One participant at our meeting on the Molecular Basis for Biological Membrane Organization and Dynamics wrote, “I learned results that will help our research tremendously; we will not have to spend a lot to establish assays and can directly test a more focused hypothesis.” Another attendee commented, “Recent developments of techniques in the fi eld were presented with relevant examples and good explanation. These can be applied within my own research group.” And new information acquired at our meetings extends to career-related issues, too; a graduate student who attended the meeting on Antibiotics and Resistance: Challenges and Solutions said, “It opened my eyes to new postdoctoral opportunities that I didn’t know were there. It was also the fi rst time I came into contact with researchers in industry. So overall I feel that I’m better equipped to make the right career choices after my PhD.”

54 Maximizing Connectivity The third principle is maximizing connectivity among the attendees. It is one thing to have a lot of research results available for consideration, and another thing entirely to have a group of investigators exploring these results together through critical discussion. At Keystone Symposia conferences (and indeed at many other conferences), formal talks are often excellent forums for sharing data, and the subsequent question-and-answer period establishes some degree of connectivity between the speaker and audience. However, Keystone Symposia aims for much more extensive connectivity through its deliberate inclusion of unstructured time and its attention to venues that maximize encounters among attendees. The informal atmosphere at these venues – combined with unique activities focused on maximizing participation by all attendees – addresses another important aspect of connectivity: minimizing social barriers such as stage of career, institutional affiliation, nationality, gender and race or ethnicity. Our intentional focus on creating an environment for the free exchange of ideas among all attendees leads to new directions for research, better research and new relationships that extend well beyond the meeting itself.

How well did Keystone Symposia’s attention to connectivity work in 2010? A participant at Antibiotics and Resistance: Challenges and Solutions reported, “I felt welcomed and engaged through the interaction with the organizers, participants and presenters. There is noticeable readiness to discuss and even share materials.” An attendee at HIV Vaccines commented on the orientation session provided at the beginning of the meeting, “The opening session made me feel welcome. I especially made use of the advice to not feel intimidated by ‘famous’ professors. I kept this in mind throughout the whole meeting and used it to feel comfortable in engaging in conversation with many new people.”

Fostering Diversity Maximizing diversity among meeting participants is the fourth principle. Attendees with many different experiences and backgrounds – e.g., different research interests, career stages, cultures – bring a rich variety of perspectives and problem-solving approaches to the meeting and, more generally, to the challenges of biological and biomedical research. An investigator who attended New Paradigms in Cancer Therapeutics had this to say, “The diverse crowd was a welcome surprise – academic/ industry, locale and stage of career development.” Of course, diversity without connectivity provides little or no advantage, hence Keystone Symposia’s very deliberate attention to a meeting environment that fosters extensive exchange among all attendees. One aspect of our multi-faceted approach to diversity and connectivity is a unique “peer-to-peer” program directed at meeting attendees from historically underrepresented minority (URM) backgrounds. About two weeks before a Keystone Symposia meeting, our Director of Diversity in Life Science Programs, Dr. Laina King, contacts and welcomes all URM registrants and helps arrange informal get-togethers at the meeting. Overall, participants in the peer-to-peer program report feeling especially welcome and engaged at the conferences.

Inspiration The final principle that I will share is that the meeting must inspire from beginning to end. What is it that motivates students and scientists to register and travel to the meeting, to connect with one another at the meeting, to share information and to collaborate in the process of understanding data shared as well as creating new directions for research? Keystone Symposia asks a lot of our attendees. In return, however, we offer what one attendee at Synapses: Formation, Function and Misfunction characterized as “an intimate and intellectually very stimulating atmosphere.” This is achieved by creating scientific programs and environments where students and scientists are truly in their element; where day-to-day distractions fade and energy is redirected to research and discovery all day, every day; and where the convergence of information, connectivity, diversity and inspiration produces those happy accidents known as serendipity – a chance encounter with new data or a new person that leads to new insights.

5 Impact of Global Health Travel Awards Far-Reaching by Yvonne Psaila, Director of Marketing and Communications, Keystone Symposia

Forging Global Collaborations and Understanding to Combat Infectious Disease

ne of Keystone Symposia’s most impactful educational programs is the Global Health Travel Award program. Now running since 2006, this program funds the travel, lodging, food and registration costs for attendees from countries Owhere the meeting topic is a particular issue. Currently, it enables participation at infectious disease meetings in the Keystone Symposia Global Health Series. This typically involves about six conferences each year, including one conference that is held immediately before or after the Grand Challenges in Global Health conference for that program’s grant recipients. The Keystone Symposia Global Health Award program is generously funded by the Bill & Melinda Gates Foundation; currently, Keystone Symposia is midway through its second three-year grant from the Foundation. In the 2010 fiscal year, it made 219 awards to recipients from more than 50 countries, for a total of 894 awards since the program’s inception.

The vast majority of the recipients of this competitive award would not be able to attend a Keystone Symposia conference without the funding a Global Health Travel Award provides. For many, it is their first chance to travel outside their country. The most significant experience is often the opportunity to meet and interact with the world-class researchers whose work they have been following throughout their careers.

Tonny Jinny Owalla, a Master’s student in Kampala, Uganda, attended the Malaria meeting in Copper Mountain, Colorado in April 2010 on a Global Health Travel Award and said it “was really a great inspiration... It widened my understanding of host-parasite immunological and molecular interaction. This will enable me to design informed intervention studies. Secondly, presenting a poster was a great experience and gave me confidence not only in presenting but also in the quality of my work. Presentations by my peers and senior scientists were a great source of inspiration and their critical analysis/discussions improved my data interpretation skills.” Owalla also reported that the conference helped him to secure admission to a Ph.D. program and in making contact with a researcher at Washington State University that could lead to a possible collaboration.

Dr. Iheanyi Okonko, an instructor and research virologist in Nigeria, echoed these sentiments following his experience at the meeting on Overcoming the Crisis of TB and AIDS in Arusha, Tanzania in October 2009. “My attendance has greatly increased my knowledge of recent developments in prevention and control of HIV/AIDS as well as other drug-resistant organisms. I am better equipped to lecture laboratory scientists and medical, dental and microbiology students in issues of infectious disease.”

While on the surface the most obvious beneficiaries of this program are the Travel Award recipients themselves, the program really is a two-way street that reaps numerous fruits for all participants. Scientists focused on challenging, seemingly intractable health issues such as HIV/AIDS, tuberculosis, malaria and drug resistance hugely benefit from gaining the first-hand perspective of the researchers and healthcare providers who are on the frontlines fighting these diseases. Dr. Stefan H.E. Kaufmann, a Professor at Max Planck Institute for Infection Biology in Berlin, member of Keystone Symposia’s Scientific Advisory Board and co-organizer of the TB and AIDS meeting, could not agree more. “These young researchers not only study infectious diseases but are best aware of their social, economic and health impact. Accordingly, it is not only they who benefit from Keystone Symposia, we from the industrialized world also directly benefit from their deep, personal insights into these health threats.” Stefan Kaufmann, Ph.D., right, at Global Health meeting in Seattle. The program is primarily administered at Keystone Symposia by Jeff Lehman, Scholarship Coordinator, who recently replaced Ksenia Shambarger when she left the organization in May 2010 after five years to pursue a nursing career. Under the direction of Kathy Tavares, Program Development/Implementation Supervisor, and Jeannie Dalrymple, Senior Director of Program Development and Implementation, Jeff also administers Keystone Symposia Scholarships and Underrepresented Minority (URM) Scholarships. Dr. Laina King, Director of Diversity in Life Science Programs, works with Jeff as well on URM scholarships.

In contrast to scholarship recipients who receive reimbursement after supplying receipts once a meeting is concluded, Global Health Travel Award recipients do not have to pay for any of the costs in advance. Planning their travel and lodging therefore requires an enormous amount of attention to detail that involves numerous departments and personnel at Keystone Symposia including the Finance Department and on-site representatives who explain everything from using the debit cards provided for

6 Impact of Global Health Awards Far-Reaching

incidentals to negotiating the phone system to avoid hefty hotel costs.

In April 2010, all rose to the challenge when 13 Global Health Travel Award recipients at the Malaria and Vector- Borne Diseases conferences were stranded in Colorado after the Eyjafjallajokull volcanic eruption in Iceland caused massive travel disruptions – a vivid reminder from Mother Nature of just how globally interconnected we really are. Staff scrambled to re-route the affected individuals where possible and to provide them lodging at a hotel near Denver International Airport while they waited for their flights. Chief Scientific Officer Andrew Robertson took the group to dinner in Denver, joined by some of his acquaintances from the University of Colorado Health Sciences Center. What could have been the ultimate travel nightmare actually prolonged a positive experience for many Travel Awardees.

In this spirit, Keystone Symposia is continually striving to enhance the program. For instance, there is increasing demand for funding of attendance at meetings outside the traditional Global Health Series, since diabetes, cardiovascular disease and other issues are of growing concern in the developing world. For 2011, to make the Global Travel Award program even more effective, Keystone Symposia has initiated a pre-meeting course that will typically convene the afternoon before the evening keynote address. Launched at the October 2010 Above: Global Health conference in Arusha, Tanzania on Overcoming the Crisis of TB meeting on Immunological Mechanisms of Vaccination and AIDS. Below: Global Health joint meetings on Malaria and Vector-Borne Diseases in Colorado, USA, including, at left, Travel Awardees stranded in Denver by the volcano. in Seattle, where it was very well received, this will Bottom: Pre-meeting course for Awardees at Vaccination conference in Seattle, USA. essentially give Travel Awardees a crash course in case there are areas where they are less conversant with the research topic or terminology. The chance to interact with teachers like Drs. Bali Pulendran, Shane Crotty and Rafick Sekaly, who instructed the course in Seattle, is an invaluable additional benefit.

Keystone Symposia is very grateful to the Bill & Melinda Gates Foundation for making this valuable program possible. Its impacts are spreading far and wide.

2010 Global Health Series Meetings Overcoming the Crisis of TB and AIDS – 92 awardees HIV Biology and Pathogenesis – 33 awardees Antibiotics and Resistance: Challenges and Solutions – 25 awardees HIV Vaccines – 32 awardees Malaria: New Approaches to Understanding Host-Parasite Interactions – 26 awardees Molecular Targets for Control of Vector-Borne Diseases: Bridging Lab and Field Research – 11 awardees 7 Malaria: New Approaches to Understanding Host-Parasite Interactions joint with Molecular Targets for Control of Vector-Borne Diseases: Bridging Lab and Field Research Copper Mountain Resort, Copper Mountain, Colorado, USA, April 11–16, 2010

“The opportunity of attending this meeting is a great fortune to me to learn from many researchers new techniques that I will bring back to progress my research.” – Wachiraporn Tipsuwan, BIOTEC, Thailand (Global Health Travel Awardee)

8 2010 performance

The charts below are intended to provide a snapshot of Keystone Symposia’s 2010 fi nances and activities. Please visit www.keystonesymposia.org/AboutUs/AnnualReport.cfm to view the full audited statement of fi nancial condition and statement of activities for the fi scal year July 1, 2009 – June 30, 2010.

2010 Expenditure Breakdown

Educational 83.57% Programs

Fundraising & 3.85% Development

Management 12.58% & General

A full 83.57% of Keystone Symposia’s expenditures go toward educational programs including meeting programs, scholarships, travel awards and diversity initiatives.

Year-over-Year Expenditure Comparison

Educational Programs 83% 80% 77% 77% Fundraising & Development

Management & General 2% 3% 2% 4% 21% 20% 18% 13% 2007 2008 2009 2010

2010 Revenue Breakdown Investment Income/ Individual Gifts Miscellaneous Income (9.16%) (.18%) Government Grants (5.04%)

Registration Fees/ Earned Income (51.75%)

Corporate/Foundation Gifts (33.87%) 9 Total Meeting Attendance & Abstract Submissions* 13,956 13,509 13,554 13,015 12,303 11,512 11,222 10,329

Attendees & Speakers 7,340 6,857 6,587 6,547 5,736 5,962 Abstract Submissions* 5,060 5,400 *abstract count does not include speaker abstracts

2003 2004 2005 2006 2007 2008 2009 2010

Average Attendance & Abstracts* per Meeting 270 252 262 244 241 242 241 237 Average Attendance

Average Number of Abstracts* 132 123 130 122 127 126 117 110 Number of Meetings

56 58 *abstract count does not 46 44 54 50 52 41 include speaker abstracts

2003 2004 2005 2006 2007 2008 2009 2010

Scholarships & Travel Awards 929 930 903

711 681 619 Scholarships 546 Underrepresented 459 Minority Scholarships

Global Health Travel Awards

2003 2004 2005 2006 2007 2008 2009 2010

10 8 2010 Attendee Demographics (based on attendee surveys)

Unknown Journalist Nonprofi t Unknown (.5%) (.67%) (2.56%) (1.46%) Postdoc (20.85%) Industry Student (13.30%) (20.09%)

Government (4.89%)

OCCUPATION SECTOR

Research Professor (14.41%) Scientist (18.29%)

Academic/ Associate Research Physician Professor (7.57%) (1.64%) Assistant Institute (77.79%) Administrator Assistant Professor (10.13%) (1.49%)

Age Over 65 Africa – non-Mediterranean (1.87%) (1.59%) Unknown (.64%) Age Unknown (.44%) Canada (4.45%) Age 55-64 Latin America (.92%) (7.68%) Age Under 30 (21.43%) Asia & Pacifi c (9.78%) Age 45-54 (19.3%)

REGION AGE

Europe & Eurasia (25.84%) Age 30-34 Age 35-44 (20.3%) United States (29.26%) (55.79%) Middle East & North Africa (.71%)

Prefer Not to Respond (6.48%) Unknown (1.34%) Unknown (.54%) Bi-Cultural (1.87%) Asian (20.49%) Hispanic/Latino (3.17%)

Black/African American (2.27%) American Indian/ Alaska Native (.48%)

Pacifi c Islander (.08%) ETHNIC PREVIOUS BACKGROUND ATTENDANCE

Previously Caucasian Attended a Never Attended (63.82%) Keystone Symposia Keystone Symposia Meeting (51.93%) Meeting Before (47.53%)

11 donor support

eystone Symposia is fortunate to receive substantial ongoing support from the pharmaceutical and biotechnology industries, charitable foundations and individuals. We are also honored to be the recipient of numerous grants from Kthe US National Institutes of Health and other government agencies around the world. These gifts and grants are used to provide scholarships for graduate students and postdoctoral fellows, travel awards for scientists from developing nations and subsidies for the travel and lodging costs of scientifi c speakers from academic and other nonprofi t laboratories and institutions.

For the 2010 meeting season, we received a total of $4.3 million from government, corporate, foundation and individual sources, as shown in the chart below. This funding supports Keystone Symposia’s mission to serve as a catalyst for the advancement of biomedical and life sciences and to accelerate applications that benefi t humankind.

Individual Gifts: $24,163 (1%)

In-Kind Gifts: Corporate Gifts: $874,068 $1,049,850 (20%) (25%)

Other Government Grants: $232,664 (5%)

US Federal Government Grants: $724,148 (17%) Foundation Gifts: $1,361,662 (32%)

Keystone Symposia gratefully acknowledges donors who gave in the 2010 fi scal year. Their generous support makes possible the outstanding scientifi c quality of our meetings and unsurpassed opportunities for interaction and collaboration among participants. To make a gift, please contact the Development offi ce by telephone at 970-262-1474 or by e-mail at [email protected]. “Future of Science Fund” individual donations can also be made over the Internet at www.keystonesymposia.org/ScienceFund.

Christopher Atwood, D.Min. Director of Development, Keystone Symposia

129 Note: The listings on this page and the next five pages reflect donations for the fiscal year beginning July 1, 2009 and ending June 30, 2010.

SUSTAINING BENEFACTORS Donors making a three-year commitment of at least $50,000 per year. Their generous support is crucial to sustain Keystone Symposia’s ability to plan future scientific conferences focused on emerging topics and excellence in science.

Agency for Science, Technology and Research (A*STAR) Bill & Melinda Gates Foundation National Institute of Diabetes and Digestive and Kidney Diseases, NIH National Institute of General Medical Sciences, NIH, Minority Access to Research Careers (MARC) Novo Nordisk A/S Science Foundation Ireland Singapore Tourism Board Takeda Pharmaceutical Company Limited

BENEFACTORS Donors of $50,000 or above. We are very grateful for their extraordinary commitment to our mission to connect the scientific community and accelerate discoveries that benefit society. Special thanks to those organizations that provide consistent, annual Benefactor-level support. Amgen Inc. Genentech BioOncology Merck & Co., Inc. Office of AIDS Research, NIH Pfizer Global Research & Development

SUSTAINING SPONSORS Donors making a three-year commitment of $25,000 to $49,999 per year. Their generous support is crucial to Keystone Symposia’s ability to plan future scientific conferences focused on emerging topics and excellence in science.

Alfred P. Sloan Foundation Alnylam Pharmaceuticals, Inc. Astellas Pharma Inc. Celgene Corporation Genzyme Corporation Gilead Sciences, Inc. Hoffmann-La Roche, Inc. Novartis Institutes for BioMedical Research Regulus Therapeutics Inc. Sangamo BioSciences, Inc. Santaris Pharma A/S

SPONSORS Donors contributing $25,000 to $49,999. These generous gifts allow us to convene meetings in a wide variety of important areas, many of which are in the early stages of research. Special thanks to those organizations that provide consistent, annual Sponsor-level support.

Abbott Laboratories Isis Pharmaceuticals, Inc. AstraZeneca Pharmaceuticals, L.P. Japan Society for the Promotion of Science Bristol-Myers Squibb Company Johnson & Johnson Pharmaceutical Research Burroughs Wellcome Fund & Development, L.L.C. Eli Lilly and Company Monsanto Company GlaxoSmithKline sanofi-aventis Gordon and Betty Moore Foundation Simons Foundation ImClone Systems Corporation 13 Donor Support

DIRECTORS’ FUND BENEFACTORS The following donors with unrestricted gifts of $50,000 or more enabled Keystone Symposia’s President/CEO and Directors to organize meetings at their discretion in a variety of important areas, many of which are in the early stages of research.

Genentech BioOncology Pfizer Global Research & Development Merck & Co., Inc. Takeda Pharmaceutical Company Limited Novo Nordisk A/S

DIRECTORS’ FUND SPONSORS The following donors with unrestricted gifts from $25,000–$49,999 also provided invaluable support to the Directors’ Fund.

Abbott Laboratories Hoffmann-La Roche, Inc. Alnylam Pharmaceuticals, Inc. Isis Pharmaceuticals, Inc. Astellas Pharma Inc. Johnson & Johnson Pharmaceutical Research AstraZeneca Pharmaceuticals, L.P. & Development, L.L.C. Bristol-Myers Squibb Company Monsanto Company Celgene Corporation Novartis Institutes for BioMedical Research Eli Lilly and Company Regulus Therapeutics Inc. Genzyme Corporation Sangamo BioSciences, Inc. Gilead Sciences, Inc. Santaris Pharma A/S GlaxoSmithKline sanofi-aventis

DIVERSITY PROGRAM SUPPORT Keystone Symposia is grateful to the following 2010 supporters of its Diversity in Life Science Programs.

Amgen Inc. National Institute of General Medical Sciences (NIGMS), Alfred P. Sloan Foundation NIH, Minority Access to Research Careers (MARC)

PARTNERS, PATRONS, DONORS, CONTRIBUTORS Keystone Symposia wishes to thank the following donors to the 2010 meeting series. Their generous support makes possible the outstanding scientific quality of our meetings and unsurpassed opportunities for interaction among attending scientists.

PARTNERS ($10,000–$24,999) BioMarin Pharmaceutical Inc.* National Institute of Environmental Health Sciences, NIH Juvenile Diabetes Research Foundation International Structural Genomics Consortium Landes Bioscience* The Ellison Medical Foundation National Institute of Allergy and Infectious Diseases, NIH The Uehara Memorial Foundation

PATRONS ($5,000–$9,999) AbD Serotec* Novartis Pharma KK Japan Avanti Polar Lipids, Inc. Novus Biologicals, Inc.* Cell Signaling Technology, Inc. Ono Pharmaceutical Co. Ltd. Daiichi Sankyo Co., Ltd. Otsuka America Pharmaceutical, Inc.* Development, The Company of Biologists Ltd. Rigel Pharmaceuticals, Inc.* Fáilte Ireland Seahorse Bioscience, Inc.* Integrated DNA Technologies* The Queensland Government, through the Department of Invitrogen Corporation* Employment, Economic Development and Innovation’s Medivation, Inc. Office of Biotechnology and Therapeutic Medicines and Nacalai Tesque, Inc. Devices

*Indicates a gift to the Directors’ Fund, which allows Keystone Symposia’s President/CEO and Directors to schedule and support meetings at their discretion. 14 PARTNERS, PATRONS, DONORS, CONTRIBUTORS (continued)

DONORS ($2,500–$4,999) Abcam plc HypOxygen* AdipoGen International* International Rett Syndrome Foundation ALPCO Diagnostics* Isotec, a member of the Sigma-Aldrich Group* Alzheimer’s Drug Discovery Foundation Kyowa Hakko Kirin Co., Ltd. Biogen Idec, Inc. Mercodia, Inc.* Biospherix, Ltd.* Millipore Corporation* Bruker BioSpin GmbH* Mitsubishi Tanabe Pharma Corporation Cayman Chemical Company, Inc.* Promega Corporation* CEDARLANE* R&D Systems, Inc.* Cephalon* Rigaku Americas Corporation* ChemoCentryx, Inc.* Royal Society of Chemistry* Chroma Technology Corporation* Rules-Based Medicine, Inc.* CovX Research LLC (Pfizer) Ruskinn & Baker BioScience Solutions* CSIRO Santa Cruz Biotechnology, Inc.* CytoAnalytics* STEMCELL Technologies, Inc.* Dainippon Sumitomo Pharma Co., Ltd.* StemCells, Inc. Dendreon Corporation* Syngenta Biotechnology, Inc.* Emerald BioSystems, Inc.* Thermo Fisher Scientific* Exelixis, Inc.* Transposagen Biopharmaceuticals, Inc.* GTx, Inc.* Vitro Biopharma*

CONTRIBUTORS (up to $2,499) American Heart Association’s Council on Basic Cytokinetics, Inc. Cardiovascular Sciences Journal of Lipid Research Asubio Pharma Co., Ltd.* Sidney E. Frank Foundation Bristol-Myers Squibb Company

US GOVERNMENT GRANTS Keystone Symposia appreciates grants to support various 2010 meetings received from the following government agencies: National Institutes of Health (NIH): National Cancer Institute (NCI) National Heart, Lung, and Blood Institute (NHLBI) National Institute on Aging (NIA) National Institute of Allergy and Infectious Diseases (NIAID) National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Institute of Environmental Health Sciences (NIEHS) National Institute of General Medical Sciences (NIGMS) National Institute of Mental Health (NIMH) National Institute of Neurological Disorders and Stroke (NINDS) National Science Foundation (NSF)

*Indicates a gift to the Directors’ Fund, which allows Keystone Symposia’s President/CEO and Directors to schedule and support meetings at their discretion.

15 Future of Science Fund

These generous alumni of previous meetings and others with a passion for ensuring a future of scientific discovery that benefits humankind have made gifts in the fiscal year ending June 30, 2010 to support the Keystone Symposia Future of Science Fund. Through their generosity, we are able to provide scholarships and travel awards to the next generation of biomedical and life scientists, whose education and careers are enhanced by the opportunity to attend meetings and interact with the world’s leading senior scientists.

In addition to funding for general and underrepresented minority scholarships and travel awards for investigators coming from countries most affected by topics of specific meetings, Future of Science Fund supporters can also contribute to help us meet general meeting program expenses, as well as program costs for specific meetings of their choice. If you made a recent contribution to this education fund before its scope was expanded and it was accordingly re-named, you are here gratefully acknowledged as a Future of Science Fund supporter.

President’s Circle ($10,000+) Keystone Patrons (continued) Keystone Contributors ($10–$99) Katharine Holloway, with matching gift Stephen Anderson from Merck Partnership for Giving Paulo R.Z. Antas Kyoko Imanaka-Yoshida Fatih Arslan Founders’ Society ($5,000–$9,999) Mark H. Kaplan Michelle C. Barton Masayasu Kojima Donald E. Bashford Shigeo Koyasu Helen Benes Keystone Champions ($1,000–$4,999) Takeshi Kurose Lakshmi Bhagat Sue Aiken Michal Laniado Schwartzman Akshay A. Bhinge Myles Brown, Judy Garber Mitchell A. Lazar Raymond B. Birge Edward A. Dennis Joel Linden Ramireddy Bommireddy Vishva M. Dixit Marcia MacDonald Steven Armen Boyd Edison T. Liu Mahin D. Maines Kerstin Brinkmann Walter H. Moos, Susan M. Miller Michael H. Malim Astrid E. Cardona Roy G. Michell Charitable Foundation and Trust Suraj P. Manrao Pere-Joan Cardona Craig B. Thompson Kaoru Masuyama Erin E. Carlson, in memory Juleen R. Zierath Raghavendra G. Mirmira, in memory of Eric Carlson Anonymous (2) of Professor Howard S. Tager Luiza Antunes Castro-Jorge Robert C. Murphy Dhyan Chandra Keystone Benefactors ($500–$999) Uhtaek Oh Hainan Chen Christopher Atwood Terry J. Opgenorth Albert Chiang Jeffrey I. Greenstein Sakol Panyim Valerio Chiurchiù Margaret A. Liu Eric M. Parker Jaebok Choi Luciano Mueller, with matching gift from Xiao-Rong Peng Tomas Cihlar Bristol-Myers Squibb Matching Gift Program Alexander Pertsemlidis Emanuele Cocucci Tony Pawson Hanno Pijl Paul J. Converse Toshio Suda Jef Albert Pinxteren, ReGenesys Austin J. Cooney Ian A. Wilson Charles H. Reynolds Jose M. Cuezva Anonymous (1) Andrew D. Robertson Michael H. Cynamon Beverly A. Rothermel, in memory Sanjoy K. Das Keystone Patrons ($100–$499) of Daphne Rothermel Xavier Deupi Alan D. Attie Roger Sabbadini Diana Diaz-Arevalo Joseph Baar Edward B. Sanders Ivan D’Orso Kenneth W. Bair Alan Sher Stein Ove Døskeland David Monty Berman Gerald Sufrin Chirapa Eamsila Ralph A. Bradshaw Doris A. Taylor Robert H. Eckel Cherié L. Butts Chanwit Tribuddharat Pearlie K. Epling-Burnette Angela Ciuffi Terry Unterman Joan Fallon Lee M. Ellis Joanne L. Viney, with matching gift from Amgen Yong Fan Beverly M. Emerson Brian F. Volkman Julian Alberto Ferreras Tekalign Deressa Eticha Lawrence J. Wangh Eugenia Flores-Figueroa Stephen W. Fesik Jean-Claude Weill Michael Forstner Henry N. Ginsberg Sally Wenzel-Morganroth Rosanne Frederick Masataka Harada Tod Woolf Lisa M. Ganley-Leal Kim A. Heidenreich Jean Zhao Sonia Carmen Garcia Caraballo, Mary J.C. Hendrix Anonymous (8) Dr. S. Eleonore Koehler

16 Keystone Contributors (continued) Keystone Contributors (continued) Keystone Contributors (continued) Yoshio Goshima William A. McLaughlin Lorraine Martina Tracey Daria Grafodatskaya Carlos O. Mendivil James B. Trager Geoffrey L. Greene Wladek Minor Tamotsu Tsukahara Justin M. Greene Masashi Miyano Gregorio Valdez Zhenheng Guo Donald T. Moir William J. Valentine Roger Gutiérrez-Juárez Paul E. Morin Bruno Vaslin Volker H. Haase David W. Mullins Sean M. Wu Young-Goo Han Karl Daniel Murray Peter Stefan Wunderli Roy Hantgan Philip M. Mwimanzi Polung Yang Thomas J. Hawke Hiroshi Nishimune Giles See How Yeo Bronwyn D. Hegarty Deborah Veis Novack Nicola Zanesi Peter V. Hornbeck Selene G. Nunez-Cruz Carlos Rodrigo Zarate Blades, Bruce H. Horwitz Kate M. O’Connor-Giles University of São Paulo Anke Huckriede Masaru Ohme-Takagi Shuo Zhang Akira Imamoto Ramavati Pal Andreas Zirlik Yuri Ivashchenko Maikel Peppelenbosch Christos E. Zois Akira Iwase Alessandra B. Pernis Anonymous (7) Susan Johnson Kylee M. Peterson Daniel M.M. Jorge Patrícia Dillenburg Pilla Michael A. Kalwat Cherylene Plewa, with matching gift from Amgen Kuniyuki Kano Patrick J. Pollard Mitsuo Kato Ashok V. Purandare Melkam A. Kebede Charani Ranasinghe Clara L. Kielkopf Timothy E. Reddy InKyeom Kim Jutta Reinhard-Rupp James I. Kim Robert Douglas Sammons Atsushi Kitani Iryna Saranchova Christine Kocks Shuji Sato Jörg Köhl Bernhard Schermer Dong Kong Julian I. Schroeder Alan J. Korman Stefan Schulz Eleonora Kurtenbach Matthew M. Seavey Nathalie Labrecque Jonathan R. Seckl Andrew M. Leidal Mikihito Shibata Robin G. Lerner Rebecca A. Shilling David B. Lewis Dusanka Skundric Yunsheng Li Catharine L. Smith Xinhua Lin Jonathan W. Snow Paul F. Lindholm Corrado Spadafora Brendan J. Loftus Daniel E. Speiser Amy C. Lossie Ivan Stamenkovic Nicholas James Maness John A. Tainer Nobuyuki Matoba André Tanel Nina Mayorek Clifford Graham Tepper, in memory Stuart G. McLaughlin of Loretta Tepper

17 Gift-in-Kind Donor Support

The following publishers, societies and other organizations provided in-kind marketing and advertising support that helped publicize the 2010 Keystone Symposia meeting series.

BENEFACTORS ($50,000+) DONORS ($2,500–$4,999) BioMed Central Ltd Beatson Institute for Cancer Research Cell Press Elsevier Science and Technology Books Nature Publishing Group IBC Life Sciences The Scientist Organization for Autism Research Phacilitate Limited SPONSORS ($25,000–$49,999) SAGE Publications BioTechniques Select Biosciences Ltd. Cold Spring Harbor Laboratory The Company of Biologists Ltd. Public Library of Science Royal Society of Chemistry CONTRIBUTORS (up to $2,499) American Association of Pharmaceutical Scientists PARTNERS ($10,000–$24,999) American Federation for Aging Research American Association for the Advancement of Science American Society for Cell Biology Drug Discovery Today American Society for Human Genetics FOCIS (Federation of Clinical Immunology Societies) AusBiotech Mary Ann Liebert, Inc. Publishers Australian and New Zealand Society for Cell and Pubget Inc. Developmental Biology S. Karger AG British Pharmacological Society Springer Science+Business Media B.V. Colorado BioScience Association The American Chemical Society Com & Co SARL The Rockefeller University Press – The Journal of Cell Biology Elsevier Inc. The Rockefeller University Press – The Journal of Experimental European Life Science Journal Medicine Gerontological Society of America Gold Coast Convention Bureau PATRONS ($5,000–$9,999) International Society for Biological Therapy of Cancer International Society for Stem Cell Research (ISSCR) American Society for Biochemistry and Molecular Biology Journal of Clinical Investigation Proceedings of the National Academy of Sciences Society for Developmental Biology The Protein Society The following companies generously agreed to forego reimbursements for speaker travel and lodging expenses in order to support 2010 Keystone Symposia meeting programs.

Abbott Laboratories Merck Research Laboratories Amgen Inc. Merck Vaccine Division Amunix Inc. Metabasis Therapeutics, Inc. AstraZeneca India Pvt Ltd Micromet, Inc. AstraZeneca Pharmaceuticals, L.P. Minase Research Institute, Ono Pharmaceutical Co. Ltd. AstraZeneca R&D Boston Monsanto Company Avid Radiopharmaceuticals, Inc. Novartis Institutes for BioMedical Research Bayer BioScience N.V. Ono Pharmaceutical Co.Ltd. Bristol-Myers Squibb Company Opsona Therapeutics Eli Lilly and Company Orexigen Therapeutics, Inc. Genentech, Inc. Pfizer Biopharmaceuticals Genzyme Corporation Pfizer Inc. GlaxoSmithKline Regeneron Pharmaceuticals, Inc. GlaxoSmithKline Biologicals S.A. sanofi-aventis GlaxoSmithKline R&D China Sanofi-Aventis Pharma Deutschland GmbH Heptares Theraputics Ltd Schering-Plough Research Institute Ipsen/Biomeasure Schrödinger Isis Pharmaceuticals, Inc. Seattle Genetics, Inc. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Tekmira Lilly UK Tibotec BVBA MedImmune Vertex Pharmaceuticals Incorporated 18 Merck & Co., Inc. New Insights into Healthspan and Diseases of Aging: From Functional to Molecular Senescence

Granlibakken Resort, Tahoe City, California, USA, January 31 – February 5, 2010 “This was my first Keystone Symposia meeting, and it far surpassed my wildest expectations.” – Michael O. Thorner, M.D., University of Virginia, USA (speaker)

19 Board of Directors (as of Dec. 31, 2010) Juleen R. Zierath, Ph.D. Terry J. Opgenorth, Ph.D. Chair of the Board, Keystone Symposia Chief Operating Officer, NeoTREX Professor, Molecular Medicine and Surgery, Karolinska Institutet CSU Ventures, Inc., Colorado State University Craig B. Thompson, M.D. Tony Pawson, Ph.D. Secretary of the Board Senior Investigator Chair, ScientificAdvisory Board, Keystone Symposia Centre for Systems Biology, Samuel Lunenfeld Research Institute President and CEO, Memorial Sloan-Kettering Cancer Center Andrew D. Robertson, Ph.D. Walter H. Moos, Ph.D. Chief Scientific Officer, Keystone Symposia Treasurer of the Board Alan Sher, Ph.D. Chair, Finance Committee, Keystone Symposia Bethesda, Maryland Vice President, Biosciences Division, SRI International Ian A. Wilson, Ph.D., Sc.D., FRS James W. Aiken, Ph.D. Professor, Department of Molecular Biology and The Skaggs President and Chief Executive Officer, Keystone Symposia Institute for Chemical Biology, The Scripps Research Institute Kenneth W. Bair, Ph.D. Chair, Audit Committee, Keystone Symposia EMERITUS BOARD MEMBERS Senior Vice President and Head, Research and Development Forma Therapeutics, Inc. Ralph A. Bradshaw, Ph.D. Raymond N. DuBois, M.D., Ph.D. Professor Emeritus, Physiology and Biophysics Executive Vice President and Provost College of Medicine, University of California, Irvine The University of Texas MD Anderson Cancer Center Professor in Pharmaceutical Chemistry and Deputy Director of Mass Spectrometry Facility, University of California, San Francisco Beverly M. Emerson, Ph.D. Robert W. Craig Chair, Personnel Committee, Keystone Symposia Professor, Regulatory Biology Laboratory, The Salk Institute President Emeritus, The Keystone Center Edison T. Liu, M.D. Edward A. Dennis, Ph.D. Chair, Globalization Committee, Keystone Symposia Professor, Chemistry, Biochemistry and Pharmacology Executive Director, Genome Institute of Singapore School of Medicine, University of California, San Diego Margaret A. Liu, M.D. Curtis C. Harris, M.D. Chair, Development Committee, Keystone Symposia Chief, Laboratory of Human Carcinogenesis ProTherImmune; Visiting Professor, Karolinska Institutet NCI/National Institutes of Health

Gary J. Nabel, M.D., Ph.D. Note: All Board and Emeritus Board Members are also members Bethesda, Maryland of Keystone Symposia’s Scientific Advisory Board.

Staff (as of Dec. 31, 2010) James Aiken, Chief Executive Officer Karen Fitzpatrick, Assistant Director of Development Pamela Daugherty, Chief Financial Officer Heather Gerhart, Senior Grants Coordinator/Program Analyst Andrew Robertson, Chief Scientific Officer Kelley Harmon, Accounting Clerk Jeannie Dalrymple, Senior Director, Program Development Lindsey Heilmann, Conference Coordinator & Implementation Jenny Hindorff, Program Implementation Assistant Linda Hrycaj, Senior Director, Strategic Planning Kellan Hoover, Publication Production Coordinator Christopher Atwood, Director, Development Mike Lachata, Information Technology Programmer Heidi Daetwyler-Simpson, Director, Meeting Management Jeff Lehman, Scholarship Coordinator Laina King, Director, Diversity in Life Science Programs Phyllis McNeil, Attendee Services Representative Tanya Muller, Director, Information Technology Allison Ogdon, Program Development Coordinator Yvonne Psaila, Director, Marketing & Communications Annie Page, On-Site Staff Mary Jo Roal, Director, Human Resources McKennzie Rains, Administrative & Research Assistant, Development David Adamson, On-Site Staff Grace Roath, Office Manager Arne Ahlstrom, On-Site Staff Julie Roll, On-Site Staff Cathy Banks, Web Developer/Systems Analyst David Sanchez, Manager, Attendee Services Carol Bosserman, On-Site Staff Barbara Schmid-Miller, Program Implementation Assistant Mary Brown, On-Site Staff Gwyn Schmude, Attendee Services Representative Caroline Brendel, Executive Administrative Assistant Bridget Stacy, Administrative Assistant, Diversity in Life Science Melissa Carrera, Logistics Coordinator Programs Linda Cooper, Publications Assistant Kathy Tavares, Program Development/Implementation Supervisor Amanda Deem, Assistant Director of Development Rebecca Wilkerson, Finance Assistant

20 Scientific Advisory Board (as of Dec. 31, 2010) E. Dale Abel, M.D., Ph.D. Wolf B. Frommer, Ph.D. Ronald T. Raines, Ph.D. Professor of Medicine, Biochemistry Plant Biology Professor, Departments of Biochemistry and Chemistry and Human Genetics Carnegie Institution for Science University of Wisconsin–Madison Chief, Division of Endocrinology, Douglas R. Green, Ph.D. Roger R. Reddel, Ph.D. Metabolism and Diabetes Doherty Chair of Immunology Director Investigator, Program in Molecular Medicine Department of Immunology Children’s Medical Research Institute, Sydney Josie I. Johnson Professorship in Molecular Biology, St. Jude Children’s Research Hospital Medicine and Biochemistry Charles “Chuck” H. Reynolds, Ph.D. University of Utah School of Medicine Philip D. Gregory, Ph.D. Head, Discovery Technologies Chief Scientific Officer, Research Ansaris, Inc. Stephen L. Brenner, Ph.D. Sangamo Biosciences, Inc. Vice President of Molecular Biosciences Juan Rivera, Ph.D. Bristol-Myers Squibb Company Diane E. Griffin, M.D., Ph.D. Deputy Director, Intraumural Research Program Professor and Chair Chief, Laboratory of Molecular Immunogenetics Leslie J. Browne, Ph.D. Molecular Microbiology and Immunology and Molecular Immunology Section President and CEO John Hopkins Bloomberg School of Public Health NIAMS, National Institutes of Health Senesco Technologies, Inc. Heidi E. Hamm, Ph.D. Cristina M. Rondinone, Ph.D. Thomas F. Bumol, Ph.D. Professor and Chair, Department of Pharmacology Director, Research, Metabolic and Vascular Diseases Vice President, BioTechnology Research Vanderbilt University School of Medicine Roche Lilly Research Laboratories President and Site Head Jacqueline E. Heard, Ph.D. Nadia A. Rosenthal, Ph.D. Applied Molecular Evolution, Inc. and Platform Lead, Yield Program, Biotechnology Division Director of EMBL Monterotondo Lilly Biotechnology Center – San Diego Monsanto Company Mouse Biology Unit European Molecular Biology Laboratory Judith Campisi, Ph.D. Kim A. Heidenreich, Ph.D. Professor, Buck Institute for Age Research Professor, Department of Pharmacology Mario D. Saltarelli, M.D., Ph.D. University of Colorado Denver (UCHSC) Divisional Vice President, GPRD Arturo Casadevall, M.D. Neuroscience Development Professor and Chair, Microbiology and Immunology Stefan H.E. Kaufmann, Ph.D. Abbott Laboratories Albert Einstein College of Medicine Professor, Immunology, Department of Immunology Max Planck Institute for Infection Biology Martin Schneider, Ph.D. Robert L. Coffman, Ph.D. Senior Vice President, Global Therapeutical Research Vice President and Chief Scientific Officer Elliott D. Kieff, M.D., Ph.D. Professor, Global Drug Discovery Dynavax Technologies Albee Professor Bayer Schering Pharma AG Medicine, Microbiology and Molecular Genetics Max D. Cooper, M.D. Harvard University Stephen J. Simpson, Ph.D. Georgia Research Alliance Eminent Scholar Life Sciences Directorate Professor of Pathology and Laboratory Medicine Laura L. Kiessling, Ph.D. Science Foundation Ireland Emory University School of Medicine Hilldale Professor of Chemistry Laurens Anderson Professor of Biochemistry Frank J. Slack, Ph.D. Alan J. Cross, Ph.D. Department of Chemistry and Biochemistry Professor Chief Scientist, CNS and Pain Innovative Medicines University of Wisconsin–Madison Molecular, Cellular and Developmental Biology AstraZeneca Pharmaceuticals Yale University Victor E. Kotelianski, M.D., Ph.D. Manoj C. Desai, Ph.D. Vice President, Research, Biology Didier Y.R. Stainier, Ph.D. Vice President, Medicinal Chemistry Alnylam Pharmaceuticals, Inc. Professor, Department of Biochemistry and Biophysics Gilead Sciences, Inc. School of Medicine Karolin Luger, Ph.D. Vishva M. Dixit, M.D. University of California, San Francisco HHMI Investigator and Professor Vice President, Research, Physiological Chemistry Department of Molecular Biology and Biochemistry Doris A. Taylor, Ph.D. Genentech, Inc. Colorado State University Medtronic Bakken Chair of Physiology and Medicine Robert H. Eckel, M.D. Director, Center for Cardiovascular Repair Elizabeth M. McNally, M.D., Ph.D. Charles A. Boettcher Endowed Chair in Atherosclerosis Department of Integrative Biology and Physiology Professor Professor of Medicine and of Physiology and Biophysics University of Minnesota Department of Medicine and Human Genetics Program Director, Adult GCRC, Medicine/Endocrinology University of Chicago Thomas Tuschl, Ph.D. University of Colorado Denver HHMI Investigator and Associate Professor Anschutz Medical Campus John McPherson, Ph.D. Laboratory of RNA Molecular Biology Senior Vice President and Head of Biologics Martin P. Edwards, Ph.D. The Rockefeller Institute Research and Development, Genzyme Corporation Vice President, Cancer Chemistry, Pfizer La Jolla Jo L. Viney, Ph.D. Donald W. Nicholson, Ph.D. Lee M. Ellis, M.D. Executive Director, Inflammation Research Vice President, Worldwide Discovery Head, R&I Professor, Cancer Biology and Surgical Oncology Amgen Inc. Merck & Co., Inc. University of Texas MD Anderson Cancer Center Nicolai R. Wagtmann, Ph.D. Hiroyuki Odaka, Ph.D. I. Sadaf Farooqi, Ph.D., FRCP Vice President and Head of Inflammation Biology General Manager, Pharmaceutical Research Division Wellcome Trust Senior Clinical Fellow Biopharmaceuticals Research Unit Takeda Pharmaceutical Company Limited and Reader in Human Metabolism Novo Nordisk A/S Metabolic Research Laboratories Anne O’Garra, Ph.D., FRS, FMedSci Michael J.O. Wakelam, Ph.D. University of Cambridge Head, Division of Immunoregulation Institute Director, The Babraham Institute MRC National Institute for Medical Research Peter M. Finan, Ph.D. David R. Webb, Ph.D. Director, Pathways Biology Eric M. Parker, Ph.D. Vice President, Research Developmental and Molecular Pathways Senior Director and Neuroscience Site Lead Neurology Celgene Corporation Novartis Institutes for BioMedical Research Merck Research Laboratories, Merck & Co., Inc. Kenneth F. Wertman, Ph.D. Curt R. Freed, M.D. Catherine E. Peishoff, Ph.D. Scientific Director, Tucson Professor and Head Vice President, Associate Vice President, Discovery Research Division of Clinical Pharmacology and Toxicology Computational and Structural Chemistry Chemical and Analytical Sciences University of Colorado Denver School of Medicine GlaxoSmithKline Pharmaceuticals sanofi-aventis U.S. PO Box 1630 Silverthorne, Colorado 80498 • USA 1-970-262-1230 • 1-800-253-0685 www.keystonesymposia.org